# Pasireotide LAR in Severe Polycystic Liver Disease

> **NCT01670110** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 48 (actual)

## Conditions studied

- Somatostatin Analogs
- Polycystic Liver Disease
- Autosomal Dominant Polycystic Kidney Disease
- Autosomal Dominant Polycystic Liver Disease

## Interventions

- **DRUG:** Pasireotide LAR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01670110
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670110, "Pasireotide LAR in Severe Polycystic Liver Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01670110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*